Apple buys Gliimpse to expand personal health data capabilities

apple store fifth avenue new york

Apple ($AAPL) has opened its wallet to build out its health data capabilities. The deal, which was struck earlier this year but only uncovered by Fast Company this week, sees Apple buy three-year-old personal health data startup Gliimpse.

Sticking to its M&A playbook, Apple has said nothing about the acquisition beyond a confirmation of the deal. But, while Apple is keeping shtum, its move into healthcare and research through HealthKit, ResearchKit and Watch and the nature of Gliimpse’s business hint at how the takeover may support its plans to make medical data another cornerstone of its $234-billion-a-year business.

Anil Sethi, a serial entrepreneur who made his name running Sequoia Software before moving into health startups, and Karthik Hariharan founded Gliimpse to stop HIPPA and a lack of interoperability from preventing people from accessing and sharing their health data. The company had a fairly low profile until this week, but has clearly done enough to attract the interest of Apple.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Gliimpse is designed to enable Americans to take control of their personal health data. Users can pull in files from the hospitals, laboratories and pharmacies that make up the U.S. healthcare system. The platform then extracts data from the documents, enabling users to search and create dashboards. And, having done so, users can share the combined dataset with physicians or researchers.

The research potential of such collections of health data was a key focus for Gliimpse while it was an independent company. Users of the platform had the option to anonymously donate their information to a “National Health Graph,” a resource Gliimpse hoped would turn into a “vast database of genuine health data” for use by researchers.

It is unclear how much data Gliimpse had gathered by the time it was bought by Apple, but it had got as far as sharing some records with researchers. Late last year, Gliimpse said it had shared data from breast cancer patients with researchers at Cancer Commons. Sethi is an adviser to Cancer Commons, a nonprofit that matches patients to clinical trials.

Whether the National Health Graph will survive the takeover by Apple in anything like its current form remains to be seen. The project, and Gliimpse as a whole, overlap with Apple’s ResearchKit virtual clinical trial platform and HealthKit framework, suggesting the acquired technology could be subsumed. In this scenario, the Gliimpse platform would disappear but the technology’s reach would surge.

“Apple’s big advantage is that they can build it into the [iOS] operating system alongside engaging data like that from HealthKit,” Brandon Ballinger, co-founder of Apple Watch app Cardiogram, told The Wall Street Journal.

- read FC’s article
- here’s the WSJ’s take (sub. req.)
- and the Verge’s coverage

Related Articles:
Apple Watch will become 'holy grail' in healthcare, Apple CEO says
Apple's new ResearchKit: Disruptive force in R&D or flashy red herring?
Survey: Public enthusiastic--but wary--about sharing personal health data

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.